{
    "nctId": "NCT03872791",
    "briefTitle": "A Study of KN046 in Subjects With Locally Advanced or Metastatic Triple-negative Breast Cancer",
    "officialTitle": "A Phase Ib/II Study to Evaluate Efficacy, Safety and Tolerability of KN046 Monotherapy or in Combination With Nab-paclitaxel in Subjects With Triple-negative Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Triple-negative Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1, PHASE2",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 52,
    "primaryOutcomeMeasure": "IRC assessed objective response",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Signed informed consent;\n* Age of 18 or above;\n* Histology confirmed locally advanced unresectable or metastatic triple-negative breaset cancer;\n* (KN046 monotherapy) failed at least one prior anthracycline and taxane containing systemic treatment, (KN046 plus nab-paclitaxel) systemic treatment naive;\n* Measurable disease at baseline;\n* ECOG 0-1;\n* Adequate organ functions.\n\nExclusion Criteria:\n\n* Untreated active CNS metastasis or leptomeningeal metastasis;\n* Subjects receiving immunosuppressive agents (such as steroids) for any reason should be tapered off these drugs before initiation of trial treatment;\n* Has interstitial lung disease, or a history of pneumonitis that required oral or intravenous glucocorticoids to assist with management;\n* Active autoimmune disease that might deteriorate when receiving an immunostimulatory agent; History of uncontrolled intercurrent illness; Known severe hypersensitivity reactions to antibody drug.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}